Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.
- Revenue in GBP (TTM)31.48bn
- Net income in GBP3.51bn
- Incorporated1999
- Employees90.10k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
More ▼
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| Affinivax Inc | -34.47% | 3.30bn |
| Sierra Oncology Inc | -36.52% | 2.08bn |
Data delayed at least 20 minutes, as of Dec 01 2022 17:03 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB SA | 5.11bn | 765.58m | 12.89bn | 8.56k | 16.83 | 1.64 | 11.39 | 2.52 | 4.56 | 4.56 | 30.47 | 46.94 | 0.4037 | 1.82 | 4.79 | 691,975.30 | 6.05 | 7.39 | 7.38 | 9.30 | 73.09 | 74.34 | 14.99 | 16.73 | 0.828 | 36.69 | 0.2528 | 28.56 | 8.04 | 6.85 | 44.13 | 14.21 | 29.00 | 2.48 |
| argenx SE | 217.84m | -753.87m | 18.48bn | 650.00 | -- | -- | -- | 84.85 | -16.79 | -16.79 | 4.76 | -- | -- | -- | -- | 388,289.60 | -- | -20.19 | -- | -22.86 | 83.75 | -- | -346.06 | -191.43 | -- | -7.70 | -- | -- | 1,105.73 | 98.16 | 32.90 | -- | 163.70 | -- |
| Merck KGaA | 18.80bn | 3.00bn | 19.39bn | 63.72k | 21.78 | 2.67 | 4.28 | 1.03 | 7.98 | 7.98 | 50.08 | 65.00 | 0.4598 | 1.90 | 5.18 | 361,073.30 | 7.36 | 5.00 | 9.24 | 6.60 | 62.35 | 63.17 | 16.00 | 12.09 | 0.8588 | 26.73 | 0.28 | 9.16 | 12.28 | 5.56 | 53.75 | 13.40 | 10.88 | 9.04 |
| Genmab A/S | 1.39bn | 656.15m | 25.00bn | 1.56k | 38.14 | 8.00 | -- | 17.97 | 85.71 | 85.71 | 181.62 | 408.67 | 0.4385 | -- | 2.94 | 9,890,264.00 | 20.68 | 18.87 | 22.68 | 20.07 | -- | -- | 47.17 | 42.62 | -- | -- | 0.023 | 0.00 | -16.11 | 36.10 | -36.78 | 20.44 | 50.07 | -- |
| HALEON PLC | 9.87bn | 1.50bn | 26.24bn | 22.80k | 17.49 | 0.9822 | -- | 2.66 | 0.1624 | 0.1624 | 1.07 | 2.89 | -- | -- | -- | 432,719.30 | -- | -- | -- | -- | 62.76 | -- | 15.68 | -- | 2.85 | 457.60 | 0.2888 | -- | -3.51 | -- | 21.40 | -- | -- | -- |
| Lonza Group AG | 5.13bn | 797.01m | 32.01bn | 17.15k | 40.14 | 3.63 | 25.37 | 6.24 | 12.21 | 41.87 | 78.57 | 134.94 | 0.3667 | -- | -- | 360,648.70 | 5.72 | 5.00 | 7.01 | 6.14 | 38.69 | 39.82 | 15.59 | 13.97 | -- | 13.15 | 0.1924 | 31.40 | 19.99 | 5.53 | -7.67 | 17.49 | 29.66 | 3.33 |
| Bayer AG | 43.03bn | 4.06bn | 46.96bn | 102.30k | 11.58 | 1.32 | 5.98 | 1.09 | 4.78 | 4.78 | 50.75 | 42.01 | 0.4028 | 1.60 | 4.74 | 500,386.40 | 3.82 | -1.37 | 5.10 | -1.77 | 62.32 | 59.99 | 9.48 | -3.73 | 0.7724 | 4.89 | 0.5193 | -- | 6.48 | 4.76 | 106.42 | -23.20 | 0.2547 | -5.52 |
| GSK plc | 31.48bn | 3.51bn | 57.22bn | 90.10k | 14.18 | 6.25 | 8.31 | 1.82 | 0.9918 | 3.53 | 8.63 | 2.25 | 0.4529 | 2.00 | 4.14 | 349,349.60 | 6.08 | 6.96 | 9.42 | 11.61 | 65.41 | 68.48 | 13.43 | 14.68 | 0.744 | 10.20 | 0.7173 | 94.85 | 0.044 | 4.11 | -23.73 | 36.90 | 4.50 | -4.36 |
| Sanofi SA | 38.28bn | 5.52bn | 94.61bn | 95.44k | 17.00 | -- | 13.42 | 2.47 | 5.09 | 5.09 | 35.35 | -- | -- | -- | -- | 464,659.20 | -- | 5.19 | -- | 6.23 | 69.70 | 68.06 | 14.39 | 15.36 | -- | 46.45 | -- | 66.94 | 4.83 | 2.46 | -49.38 | 7.20 | -0.387 | 2.28 |
| AstraZeneca plc | 37.45bn | 1.69bn | 171.54bn | 83.10k | 102.18 | 5.89 | 25.11 | 4.58 | 1.08 | 1.08 | 24.05 | 18.81 | 0.4484 | 1.20 | 5.13 | 450,703.20 | 2.03 | 2.62 | 2.68 | 3.66 | 79.25 | 78.90 | 4.53 | 6.61 | 0.6095 | 6.44 | 0.4546 | 196.26 | 40.58 | 10.22 | -96.50 | -49.76 | -1.01 | 1.03 |
| Novartis AG | 43.34bn | 18.07bn | 174.80bn | 108.00k | 9.04 | 3.10 | 7.57 | 4.03 | 9.18 | 9.18 | 22.25 | 26.74 | 0.4361 | 2.22 | 6.22 | 473,770.10 | 18.19 | 9.08 | 24.03 | 11.56 | 70.99 | 70.62 | 41.70 | 24.73 | 1.07 | -- | 0.3183 | 58.80 | 5.97 | 1.38 | 197.58 | 29.05 | 0.6311 | 3.44 |
| Novo Nordisk A/S | 19.40bn | 6.13bn | 178.77bn | 52.70k | 38.24 | 25.89 | 25.88 | 9.21 | 23.12 | 23.12 | 73.10 | 34.14 | 0.802 | 1.25 | 4.43 | 3,498,389.00 | 25.34 | 32.65 | 53.27 | 63.12 | 84.19 | 83.79 | 31.59 | 33.52 | 0.739 | 12.98 | 0.2530 | 50.18 | 10.91 | 4.72 | 13.33 | 4.72 | -2.23 | 6.47 |
| Roche Holding AG | 56.45bn | 12.85bn | 223.09bn | 100.92k | 17.42 | 9.78 | 12.75 | 3.95 | 17.67 | 17.67 | 77.20 | 31.46 | 0.7374 | 2.39 | 5.73 | 637,960.80 | 18.19 | 15.62 | 27.70 | 23.77 | 69.18 | 71.04 | 24.66 | 21.82 | 0.8037 | 20.32 | 0.4895 | 62.04 | 7.68 | 4.42 | -2.55 | 7.78 | -1.99 | 2.55 |
Data as of Dec 01 2022. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX
20.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 01 Nov 2022 | 145.60m | 3.58% |
| BlackRock Fund Advisorsas of 01 Nov 2022 | 123.67m | 3.04% |
| Norges Bank Investment Managementas of 01 Nov 2022 | 93.46m | 2.30% |
| BlackRock Investment Management (UK) Ltd.as of 31 Oct 2022 | 82.62m | 2.03% |
| Dodge & Coxas of 30 Sep 2022 | 82.39m | 2.03% |
| Schroder Investment Management Ltd.as of 01 Nov 2022 | 70.13m | 1.72% |
| Silchester International Investors LLPas of 01 Nov 2022 | 66.61m | 1.64% |
| BlackRock Advisors (UK) Ltd.as of 01 Nov 2022 | 62.38m | 1.53% |
| Legal & General Investment Management Ltd.as of 01 Nov 2022 | 54.97m | 1.35% |
| SSgA Funds Management, Inc.as of 01 Nov 2022 | 48.48m | 1.19% |
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
